The Honest Dose #12

There has never been a more interesting time to be paying close attention to this space.

I mean that as someone who spends most of his week reading study methodology sections, which is not everyone's idea of a good time. But the peptide and compounding world is moving faster right now than it has in years, and last week produced the single most significant regulatory development this space has seen in a long time. An FDA advisory committee reviewed seven peptides and recommended six of them for the compounding list. Almost nothing pointed that way going in. The agency's own scientific staff had reviewed all seven, applied the standard framework, and published briefing documents recommending against adding any of them. Then the committee voted the other direction on six.

What I keep coming back to is not who was right. It's how genuinely unpredictable this all turned out to be. If you had asked twenty well-informed people in this space to call that outcome a month ago, I don't think many would have landed on six of seven. And that uncertainty is not a quirk of one meeting. It is the defining condition of this entire market right now, and once you see it that way, a lot of things make more sense. It explains why vendors make claims that outrun their evidence. Why clinics position compounds differently from one another. Why the advice you get from two people who both seem knowledgeable can point in opposite directions. Nobody is standing on stable ground, because the ground has been moving, and a lot of the confident voices are confident about a landscape that keeps rearranging itself underneath them.

That's the part that makes me want to keep building this. My view is straightforward: people have the right to research and experiment with whatever compounds they choose. That's their call to make, and it isn't mine to gatekeep. But making that call well requires facts that haven't been filtered through somebody's incentive to sell you something. When the underlying situation is this fluid, the value of an honest, documented, unsponsored read on the evidence goes up, not down, because there are more gaps for motivated interpretation to fill.

So let's walk through what actually happened, what it does and doesn't change, and what the evidence underneath those seven compounds actually looks like.

Let's get into it.

The Pharmacy Compounding Advisory Committee met at the FDA's White Oak campus on July 23 and 24 to decide whether seven peptides should be recommended for the Section 503A Bulk Drug Substances List, the roster of ingredients a licensed compounding pharmacy is permitted to prepare against an individual prescription.

Day one covered BPC-157, KPV, TB-500, and MOTS-c. All four were recommended. BPC-157, KPV, and TB-500 each cleared on an identical split of eight in favor to six against with one abstention. MOTS-c passed more narrowly still, seven to five with two abstentions.

Day two covered Emideltide, which is the regulatory name for DSIP, along with Semax and Epitalon. Semax and Epitalon were both recommended. Emideltide was voted down, the only rejection across the two days.

Six recommended, one rejected, and not a single vote that wasn't close. One note on precision: the exact tallies for day two vary slightly between trade outlets, because the FDA had not published an official tally sheet as of this writing. The outcomes are not in dispute, but if you see a number here that differs by one from something you read elsewhere, that is why, and I would rather flag it than pretend to a precision the public record doesn't yet support.

This is where most of the coverage is going wrong, and it's worth being blunt.

None of these seven became an FDA-approved drug. That is not what this vote was about, and no amount of headline framing changes it. A PCAC recommendation is advisory and non-binding. The FDA is not required to follow it. Before any of these six could legally be compounded under 503A, the agency has to run a formal rulemaking process: a proposed rule, a public comment period, then a final rule. That sequence has historically taken well over a year to produce even a proposed rule after a favorable vote. Realistic pharmacy availability, if the FDA proceeds at all, runs into 2027.

So the honest status today is that nothing changed about what is legal. What changed is the direction of travel.

Here is the context I think matters most for reading this decision, and it connects directly to the point I made up top about facts and incentives.

The committee departed from its own agency's scientific staff on six of seven votes, which is unusual. Part of the explanation is who was voting. In June, the FDA added eight temporary voting members to the panel. They were nominated through the Health Secretary's office, and reporting indicates six of the eight have sold peptide products themselves. On BPC-157, KPV, and TB-500, all eight of the new appointees voted yes as a bloc. Conflict-of-interest concerns were raised publicly before and during the meeting, including in testimony from a nonprofit watchdog group.

Let me be precise about what I am and am not saying, because this is easy to misread. I am not claiming the outcome was wrong, and I am not questioning anyone's sincerity or expertise. There is a serious argument on the other side, made in good faith by clinicians and patients: people are already buying these compounds from unregulated sources with no oversight of what's in the vial, and a regulated pharmacy channel is meaningfully safer than the alternative. That is a real harm-reduction case and it was made seriously in that room.

What I am saying is that knowing who is making a decision, and what they have at stake in it, is part of reading the decision accurately. That isn't a political observation. It's the same observation the Research Quality Score makes about every compound it grades. Funding Independence is one of the seven scoring dimensions precisely because who funded work, and who stood to benefit from its result, is information you need in order to interpret the result well. It doesn't tell you a finding is wrong. It tells you how much of the interpretation to hold loosely. This week that principle applied to an advisory panel rather than a research compound, for exactly the same reason.

An advisory panel narrowly recommended six of seven peptides for a compounding list, in a direction almost nobody predicted, with a substantially reconstituted membership and over the documented recommendations of the agency's scientific staff. It is a genuine milestone, and it is not an approval. Worth holding clearly: the evidence base underneath those six compounds did not change on July 23. Not one new trial was published. What changed was who was asked, and what they concluded the existing evidence was sufficient for.

The claim: Ten thousand steps. It's the default goal on every fitness tracker ever sold, adopted by major health organizations, and treated by millions of people as the line between a healthy day and a lazy one. Miss it and the day somehow didn't count.

The reality: The number is a marketing slogan. In 1965, riding the wave of national enthusiasm for fitness that followed the Tokyo Olympics, a Japanese clockmaker called Yamasa released one of the first wearable pedometers. They named it the manpo-kei, which translates roughly to "10,000 steps meter." The figure was chosen because it was round, memorable, and easy to sell, and reportedly because the Japanese character for 10,000 looks something like a walking person. A Harvard epidemiologist who has spent years studying step counts and mortality has noted that when the device launched, there were no studies at all examining 10,000 steps. It was a brand name that escaped into the world and got mistaken for a research finding, and it has been travelling as one for sixty years.

Here's what makes this more interesting than a simple debunk: researchers eventually went and checked, and walking really is very good for you. The number is just wrong in a specific and useful direction. A 2019 study of nearly 17,000 older women found mortality benefits rising with step count but leveling off around 7,500. A meta-analysis pooling 15 international cohorts found the mortality curve flattening at roughly 6,000 to 8,000 steps for adults over 60, and 8,000 to 10,000 for adults under 60. A 2025 analysis in The Lancet Public Health put the range where meaningful reductions in mortality and chronic disease risk appear at roughly 5,000 to 7,000 steps. The relationship is not linear, and the steepest gains show up well below the magic number.

Which means the practical error runs opposite to what you'd expect. The problem isn't that people are walking too little to matter. It's that a marketing number set the bar high enough to make an all-or-nothing mindset feel reasonable, so someone who manages 6,000 steps concludes they failed, when they have actually captured most of the available benefit. The biggest returns come from moving off a sedentary baseline, not from clearing an arbitrary threshold.

The honest version of the claim: More walking is better, and the benefits are large and well-replicated across hundreds of thousands of people. But 10,000 was a 1965 product slogan, not a clinical finding, and the evidence that accumulated afterward consistently puts the point of diminishing returns lower, somewhere around 6,000 to 8,000 for most adults. If you're at 6,000 and feeling behind, you're not behind. If you're at 2,000, the single most valuable thing you can do is keep walking.

I picked this one deliberately. A memorable number, invented to sell a product, that the public adopted as science and that the actual research later half-confirmed and half-corrected, is not a bad description of how a lot of this space works.

Here's the exercise I ran this week. I pulled the RQS for all seven peptides the committee reviewed. Every one of these scores was assigned before the meeting, using the same seven-dimension rubric applied to all 53 compounds in the catalog, and I have not adjusted any of them since.

Two things stand out, and neither is a comment on whether the panel voted correctly.

The panel and the RQS were answering different questions. The RQS asks one narrow thing: how much methodological weight can the published human evidence bear. That's it. A compounding decision is a much broader question. It weighs patient need, whether approved alternatives already exist, how well the substance can be chemically characterized, safety signals, and what is already happening in an unregulated market where people are buying these compounds anyway. You can see the difference in the results. The one compound rejected was DSIP at 37, while BPC-157 at 20, the lowest score of the group, was recommended. If the votes had been tracking my scores, that ordering would look different. Reporting suggests DSIP's rejection turned substantially on a mechanistic discussion during the session about its effect on endorphin release. That's a legitimate clinical consideration for a panel to weigh, and it is simply not something the RQS measures. Neither instrument substitutes for the other, and it's useful to see plainly that they aren't measuring the same thing.

The scores didn't move, because a vote is not evidence. Not one of these seven compounds has a stronger research base today than it had on July 22. No trial was published. No replication appeared. No study design improved. What happened was a decision about what the existing evidence was sufficient to permit, which is a different kind of event entirely. If the RQS shifted every time a committee voted, it would be measuring institutional sentiment rather than research quality. It measures research, so it held still. That's the whole design intent, and this week was the clearest test of it so far.

The standing caveat applies as always: a low score is not a claim that a compound does nothing, and it never has been. Several of these seven have genuinely compelling preclinical stories, and BPC-157's animal literature is deep even though its human literature is empty. The score measures how much confidence the current human evidence can support, nothing more.

What happens next, and the timeline that actually matters.
The vote is the beginning of a process, not the end of one. For any of the six to become legally compoundable, the FDA has to initiate rulemaking, publish a proposed rule, take public comment, and issue a final rule. Historically that runs past a year just to reach the proposal stage. The first concrete signal to watch is whether the agency indicates it intends to proceed at all. There's also a distinction the market keeps collapsing: removal from the Category 2 "may not be compounded" list, which already happened back in April, a PCAC recommendation, which just happened, and actual placement on the compoundable list, which has not. Three separate legal events. Only two have occurred.

Expect the marketing to run ahead of the law, immediately.
This is the practical thing I'd most want you to carry out of this issue. Between now and whenever the FDA acts, you are going to see "FDA approved," "FDA cleared," and "now legal" attached to these six compounds by people selling them. All of those claims are false today, and the first two would remain false even if rulemaking completes, because a 503A listing is not a drug approval. If you see a vendor make that leap, you've learned something useful about that vendor, which brings me to the next item.

The vendor transparency work moves up the list.
I mentioned in Issue 10 that the emails I get are increasingly from people past the education stage and into the sourcing stage. This vote sharpens that. If a legal compounding channel eventually opens for six of these compounds, the number of sellers making confident claims goes up, not down, and the gap between the ones doing real third-party testing and the ones doing none becomes the thing that actually affects anyone's outcome. Same principle as the RQS, applied to process instead of research: objective, verifiable inputs, published openly, no endorsements. Still no date, still no vendors named. But it's the next build.

Of the four compounds the panel reviewed on day one, MOTS-c drew the closest margin, seven to five with two abstentions, and it's the one I'd most want you to understand, because it pairs some of the most interesting biology in the catalog with some of the thinnest human intervention data.

MOTS-c stands for mitochondrial open reading frame of the 12S rRNA type-c, which is a mouthful for something genuinely remarkable: a 16-amino-acid peptide encoded not by your nuclear DNA but by your mitochondrial DNA. It's one of only two mitochondrial-derived peptides in this catalog, and it was only discovered in 2015 at USC, making it one of the newest compounds anyone in this space discusses. The appeal is the mechanism. MOTS-c activates AMPK, the cell's central energy-regulation switch and the same pathway that metformin and exercise converge on. Circulating levels decline with age and rise with physical activity, and in mouse models it improves insulin sensitivity, reduces diet-induced obesity, and improves running performance in older animals. Hence its nickname, the exercise mimetic. The FDA evaluated it here for obesity and osteoporosis.

The gap is where the evidence stops. There are no completed human clinical trials of administered MOTS-c. The preclinical work is real and comes from credible places, starting with the original 2015 Cell Metabolism paper, and there is human observational data showing circulating MOTS-c levels track inversely with markers of insulin resistance. But that observational piece is the one most likely to be misread, and the distinction matters: finding that metabolically healthier people have higher MOTS-c does not establish that raising MOTS-c makes people metabolically healthier. It's equally consistent with the peptide being a marker of fitness rather than a driver of it, which the exercise-response data actively suggests. Separating those requires an intervention trial, and one hasn't been run. One more practical note, since it isn't a small detail for anyone who competes: MOTS-c carries World Anti-Doping Agency prohibited status.

At 41 it sits in the Limited band, which means early-stage human data or mixed study quality, directional but not conclusive. That's a fair summary of a compound with a coherent mechanism, a real preclinical literature, and a human intervention record that hasn't arrived yet.

RQS: 41/100 - Limited Evidence

Read the full MOTS-c profile

Hopefully that was helpful/interesting, see you next week.

-Emeka

Peptidclear.com

You're receiving this because you signed up at peptideclear.com. No sponsors. No affiliate links. Just the research, translated.